Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DO9B3Y
|
|||
| Drug Name |
AB-729
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Hepatitis B virus infection [ICD-11: 1E51.0; ICD-10: B18.1] | Phase 2 | [1] | |
| Company |
Arbutus Biopharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis B virus messenger RNA (HBV mRNA) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04820686) A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Arbutus Biopharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.